Literature DB >> 34592446

Combining repurposed drugs to treat colorectal cancer.

Diana Duarte1, Nuno Vale2.   

Abstract

The drug development process, especially of antineoplastic agents, has become increasingly costly and ineffective. Drug repurposing and drug combination are alternatives to de novo drug development, being low cost, rapid, and easy to apply. These strategies allow higher efficacy, decreased toxicity, and overcoming of drug resistance. The combination of antineoplastic agents is already being applied in cancer therapy, but the combination of repurposed drugs is still under-explored in pre- and clinical development. In this review, we provide a set of pharmacological concepts focusing on drug repurposing for treating colorectal cancer (CRC) and that are relevant for the application of new drug combinations against this disease.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Colon cancer; Drug combination; Drug repurposing

Mesh:

Substances:

Year:  2021        PMID: 34592446     DOI: 10.1016/j.drudis.2021.09.012

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  1 in total

1.  Inhaled Indomethacin-Loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC).

Authors:  Sruthi Sarvepalli; Vineela Parvathaneni; Gautam Chauhan; Snehal K Shukla; Vivek Gupta
Journal:  Pharm Res       Date:  2022-09-15       Impact factor: 4.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.